RESUMO
INTRODUCTION: Large-scale genomic studies based on DNA microarrays improve our understanding of the pathophysiology of cancers. The use of these research findings to improve diagnosis, prognosis and treatment is the current challenge of research in genomics. EXEGESIS: The article briefly describes the DNA microarrays technology and use in oncology and underlines the steps required to translate research findings of correlations between gene expression and type of cancer, outcome or response to chemotherapy into robust clinical tools. CONCLUSION: Genomic technologies available today are sufficient to develop useful molecular markers for individual patient management.
Assuntos
DNA de Neoplasias/genética , Neoplasias/genética , Análise de Sequência com Séries de Oligonucleotídeos/métodos , Antineoplásicos , Regulação Neoplásica da Expressão Gênica , Humanos , Neoplasias/tratamento farmacológico , Resultado do TratamentoRESUMO
PURPOSE: Recent development of interphase fluorescence in situ hybridization (FISH) allows analysis on non-proliferant plasma cells. We describe the most frequent genetic abnormalities in multiple myeloma and their prognostic value. CURRENT KNOWLEDGE AND KEY POINTS: Most frequent genetic abnormalities are illegitimate rearrangements involving the IGH gene at 14q32 (60% of patients), hyperdiploidy (50 to 60% of patients), chromosome 13 deletion (40 to -50% of patients), chromosome 1q gain (30 to -40% of patients) chromosome 17 deletion (10% of patients). Some of these genetics abnormalities are observed in monoclonal gammopathy of undetermined significance (MGUS), a pre-malignant state. t(4;14) and t(14;16) translocations and chromosome 17 deletion negatively impact the overall survival. Patients with these genomic aberrations should be treated with specific treatment. FUTURE PROSPECTS AND PROJECTS: Identification of genetic abnormalities is important for evaluation of prognosis and treatment protocol in multiple myeloma.
Assuntos
Mieloma Múltiplo/genética , Oncogenes/genética , Deleção Cromossômica , Cromossomos Humanos Par 1/genética , Cromossomos Humanos Par 13/genética , Cromossomos Humanos Par 14/genética , Cromossomos Humanos Par 17/genética , Rearranjo Gênico/genética , Humanos , Hibridização in Situ Fluorescente , Prognóstico , Taxa de Sobrevida , Translocação Genética/genéticaRESUMO
Multiple myeloma is a plasma cell malignancy characterized by recurrent IgH translocations and well described genomic heterogeneity. Although transcriptome profiles in multiple myeloma has been described, landscape of expressed fusion genes and their clinical impact remains unknown. To provide a comprehensive and detailed fusion gene cartography and suggest new mechanisms of tumorigenesis in multiple myeloma, we performed RNA sequencing in a cohort of 255 newly diagnosed and homogeneously treated multiple myeloma patients with long follow-up. Here, we report that patients have on average 5.5 expressed fusion genes. Kappa and lambda light chains and IgH genes are main partners in a third of all fusion genes. We also identify recurrent fusion genes that significantly impact both progression-free and overall survival and may act as drivers of the disease. Lastly, we find a correlation between the number of fusions, the age of patients and the clinical outcome, strongly suggesting that genomic instability drives prognosis of the disease.
Assuntos
Fusão Gênica , Mieloma Múltiplo/genética , Idoso , Feminino , Humanos , Cadeias Pesadas de Imunoglobulinas/genética , Cadeias kappa de Imunoglobulina/genética , Cadeias lambda de Imunoglobulina/genética , Masculino , Pessoa de Meia-Idade , Análise de Sequência de RNA , Translocação GenéticaRESUMO
In the past decade, many progresses have been made in our knowledge of the genetics of multiple myeloma. The use of molecular cytogenetic techniques has led to the identification of several recurrent (cyto)genetic abnormalities, representing either prognostic markers, or novel therapeutic targets. More global analyses of this genetic heterogeneity using expression array technologies should further extend our understanding of the disease, hopefully enabling some improvements in the treatment of the patients. The goal of this minireview is to summarize these recent advances.
Assuntos
Aberrações Cromossômicas , Mieloma Múltiplo/genética , Deleção Cromossômica , Mapeamento Cromossômico , Cromossomos Humanos Par 13 , Cromossomos Humanos Par 14 , Humanos , Mieloma Múltiplo/terapia , PloidiasRESUMO
Ploidy appears as an important parameter in both the biology and the clinical evolution of multiple myeloma. However, its evaluation requires either a successful karyotyping (obtained in 30% of the patients) or a DNA index calculation by flow cytometry (not routinely performed in myeloma). We validated a novel method based on interphase fluorescence in situ hybridization that can be utilitized to analyze almost all the patients. The method was very specific and sensitive for the detection of hyperdiploidy. Extended studies showed that most recurrent 14q32 translocations occur in nonhyperdiploid clones, and that deletions of chromosome 13 were less frequently observed in hyperdiploid clones (48 vs 66%). Further large studies are ongoing to evaluate the prognostic value of ploidy in myeloma.
Assuntos
Mieloma Múltiplo/genética , Ploidias , Progressão da Doença , Citometria de Fluxo/métodos , Humanos , Hibridização in Situ Fluorescente , Mieloma Múltiplo/sangue , Mieloma Múltiplo/patologia , Plasmócitos/patologiaRESUMO
C-cell tumors (medullary thyroid carcinoma) occur in humans and several other mammalian species. This tumor develops spontaneously with a high incidence (50%) in old Wag/Rij (Wistar-derived strain) rats. We have recently shown that calcitonin binding sites, which are present in the Wistar rats, are lost from renal medulla of the Wag/Rij rats before they reach the age of 1 month. In the present work, we investigated the distribution of calcitonin binding sites in the kidneys of first and second generation hybrids of Wistar x Wag/Rij rats. The absence of calcitonin binding sites from the renal medullas of 25% of F2 hybrids indicates that the deficiency is inherited in a Mendelian fashion and opens the way to establishing inbred strains lacking renal medullary calcitonin binding sites.
Assuntos
Calcitonina/metabolismo , Receptores de Superfície Celular/genética , Neoplasias da Glândula Tireoide/genética , Envelhecimento , Animais , Autorradiografia , Cálcio/farmacologia , Deleção Cromossômica , Cruzamentos Genéticos , Genes , Radioisótopos do Iodo , Medula Renal/metabolismo , Ratos , Ratos Endogâmicos , Receptores da Calcitonina , Receptores de Superfície Celular/análise , Especificidade da Espécie , Glândula Tireoide/metabolismoRESUMO
Genomic lesions are not investigated during routine diagnostic workup for multiple myeloma (MM). Cytogenetic studies are performed to assess prognosis but with limited impact on therapeutic decisions. Recently, several recurrently mutated genes have been described, but their clinical value remains to be defined. Therefore, clinical-grade strategies to investigate the genomic landscape of myeloma samples are needed to integrate new and old prognostic markers. We developed a target-enrichment strategy followed by next-generation sequencing (NGS) to streamline simultaneous analysis of gene mutations, copy number changes and immunoglobulin heavy chain (IGH) translocations in MM in a high-throughput manner, and validated it in a panel of cell lines. We identified 548 likely oncogenic mutations in 182 genes. By integrating published data sets of NGS in MM, we retrieved a list of genes with significant relevance to myeloma and found that the mutational spectrum of primary samples and MM cell lines is partially overlapping. Gains and losses of chromosomes, chromosomal segments and gene loci were identified with accuracy comparable to conventional arrays, allowing identification of lesions with known prognostic significance. Furthermore, we identified IGH translocations with high positive and negative predictive value. Our approach could allow the identification of novel biomarkers with clinical relevance in myeloma.
Assuntos
Variações do Número de Cópias de DNA , Cadeias Pesadas de Imunoglobulinas/genética , Mieloma Múltiplo/genética , Mutação , Translocação Genética , Alelos , Linhagem Celular Tumoral , Frequência do Gene , Rearranjo Gênico de Cadeia Pesada de Linfócito B , Sequenciamento de Nucleotídeos em Larga Escala , Humanos , Perda de Heterozigosidade , Reprodutibilidade dos TestesRESUMO
The gene coding for calcitonin was isolated and characterized in a non-mammalian vertebrate, chicken. Sequencing of the 3'-end of this gene revealed after the calcitonin coding exon, an intron followed by an exon coding for a calcitonin gene-related peptide, which displays significant amino acid sequence homology with mammalian CGRPs so far sequenced.
Assuntos
Calcitonina/genética , Galinhas/genética , Proteínas do Tecido Nervoso/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Peptídeo Relacionado com Gene de Calcitonina , GenesRESUMO
The avian calcitonin gene was isolated and sequenced; two mRNAs are expressed by tissue-specific alternate splicing. The peptides encoded by the mRNAs are the protein precursors of either calcitonin or calcitonin gene-related peptide (CGRP). Calcitonin is expressed predominantly in ultimobranchial bodies and CGRP in brain.
Assuntos
Calcitonina/genética , Galinhas/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , Encéfalo/fisiologia , Regulação da Expressão Gênica , Genes , Dados de Sequência Molecular , Homologia de Sequência do Ácido NucleicoRESUMO
Two genes code for calcitonin gene-related peptides (CGRPs). One expresses by tissue-specific alternate splicing calcitonin and CGRP I mRNAs, the other CGRP II mRNA. Calcitonin is the marker of sporadic or hereditary human medullary thyroid carcinoma (MTC). CGRP II expression is not well established in normal or tumoral thyroid. After amplification by polymerase chain reaction, CGRP I and II mRNAs were detected in six cases of MTC associated with other endocrine neoplasia (MEN IIa) and in two cases of isolated MTC. CGRP I was detected in all non-C cell tumoral thyroids (6 samples), CGRP II was barely detectable in three out of six cases. CGRP II could be a specific tumoral marker of MTC.
Assuntos
Peptídeo Relacionado com Gene de Calcitonina/genética , Calcitonina/genética , Carcinoma/genética , Neoplasias da Glândula Tireoide/genética , Sequência de Bases , Southern Blotting , Expressão Gênica , Humanos , Dados de Sequência Molecular , Oligonucleotídeos/química , Reação em Cadeia da Polimerase , RNA Mensageiro/genética , RNA Neoplásico/genética , Glândula Tireoide/fisiologiaRESUMO
Interleukin-11 is a hematopoietic cytokine that signals via the signal transducer gp130. Although gp130 is ubiquitously expressed, interleukine-11 responsiveness is restricted to cells that express the interleukine-11 receptor alpha-subunit. The interleukine-11 receptor alpha-subunit can be functionally replaced by its soluble form indicating that the transmembrane and cytoplasmic parts are not required for signal transduction. Here, we show that a recombinant fusion protein of a fragment of the human interleukine-11 receptor alpha-subunit ectodomain linked to human interleukine-11 acts as a superagonist on cells expressing gp130 but lacking the membrane-bound interleukine-11 receptor alpha-subunit. It induces acute phase protein synthesis in hepatoma cells and efficiently promotes proliferation of Ba/F3 cells stably, transfected with gp130. In these bioassays, the fusion protein of a fragment of the human interleukine-11 receptor alpha-subunit ectodomain linked to human interleukine-11 is 50 times more potent than the combination of interleukine-11 and the soluble interleukine-11 receptor alpha-subunit. Thus, our findings support the concept that covalent fusion of two soluble proteins required for receptor activation dramatically increases their bioactivity.
Assuntos
Antígenos CD/metabolismo , Interleucina-11/genética , Glicoproteínas de Membrana/metabolismo , Receptores de Interleucina/genética , Proteínas Recombinantes de Fusão/metabolismo , Proteínas de Fase Aguda/biossíntese , Sequência de Aminoácidos , Antígenos CD/farmacologia , Receptor gp130 de Citocina , Proteínas de Ligação a DNA/metabolismo , Expressão Gênica , Humanos , Interleucina-11/metabolismo , Subunidade alfa de Receptor de Interleucina-11 , Glicoproteínas de Membrana/farmacologia , Dados de Sequência Molecular , Pichia/genética , Inibidores de Proteases/metabolismo , Receptores de Interleucina/metabolismo , Receptores de Interleucina-11 , Fator de Transcrição STAT1 , Fator de Transcrição STAT3 , Transativadores/metabolismo , Transfecção , Células Tumorais CultivadasRESUMO
Long-term stable Ba/F3 transfectants (B13R alpha1 and B13R alpha2) expressing two isoforms of the human IL-IIR alpha receptor (alpha1 full length or alpha2 lacking the cytoplasmic domain) in combination with human gp130 were established. IL-11R alpha1 and IL-11R alpha2 were each expressed and detected as three bands upon Western blot analysis, with apparent molecular masses in agreement with those of the polypeptide backbone (47 and 44 kDa, respectively) with no, one or two N-linked sugars. B13R alpha1 and B13R alpha2 bound IL-11-thioredoxin with similar efficiencies and proliferated with superimposable dose-response curves to IL-11, demonstrating that the intracellular domain of IL-11R alpha has no significant contribution on ligand binding and signaling. Analysis of a set of anti-human gp130 mAbs confirmed the similar responsiveness of B13R alpha1 and B13R alpha2 transfectants.
Assuntos
Interleucina-11/farmacologia , Receptores de Interleucina/metabolismo , Animais , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Clonagem Molecular , Relação Dose-Resposta a Droga , Citometria de Fluxo , Humanos , Subunidade alfa de Receptor de Interleucina-11 , Proteínas de Membrana Lisossomal , Glicoproteínas de Membrana/metabolismo , Camundongos , Receptores de Interleucina/genética , Receptores de Interleucina-11 , Proteínas Recombinantes/metabolismo , TransfecçãoRESUMO
A panel of 14 hybridoma cell lines secreting monoclonal antibodies against the human interleukin-11 receptor alpha chain (hIL-11Ralpha) was obtained using two different approaches. Two antibodies were raised against peptides of the N- and C-terminal sequences, respectively, of the extracellular part of the hIL-11Ralpha. Another group of 12 antibodies was generated against a hybrid protein consisting of the extracellular part of the hIL-11Ralpha fused to mature full-length human IL-2. All these antibodies recognized native hIL-11Ralpha and most also recognized the denatured receptor on immunoblots after SDS-PAGE. Four different epitopes were identified on the extracellular part of the hIL-11Ralpha. One epitope, defined by the E27 antibody, is located at the N-terminus and the other three epitopes are clustered in the membrane-proximal, C-terminal region. The antibodies defining epitopes I and II recognized membrane-bound hIL-11Ralpha expressed in gp130/hIL-11Ralpha-co-transfected Ba/F3 cells. The E27 antibody cross-reacted with murine IL-11Ralpha, in agreement with the fact that the N-terminal region is highly conserved between species. The other 13 antibodies all recognized a region between amino acids 319 and 363, which is the membrane-proximal part of the hIL-11Ralpha. This region, which is less conserved between mouse and human, is shown here to be an immunodominant region. Anti-IL-11Ralpha monoclonal antibodies, which have not been described previously enabled us to explore the expression and tissue distribution of IL-11Ralpha on human peripheral blood mononuclear cells and cell lines. The antibodies provide powerful tools for the study of the regulation and function of the receptor.
Assuntos
Anticorpos Monoclonais , Citometria de Fluxo/métodos , Leucócitos Mononucleares , Receptores de Interleucina/imunologia , Receptores de Interleucina/isolamento & purificação , Sequência de Aminoácidos , Animais , Afinidade de Anticorpos , Reações Cruzadas , Epitopos , Humanos , Subunidade alfa de Receptor de Interleucina-11 , Interleucina-2/genética , Interleucina-2/imunologia , Camundongos , Dados de Sequência Molecular , Fragmentos de Peptídeos/imunologia , Receptores de Interleucina/genética , Receptores de Interleucina-11 , Proteínas Recombinantes de Fusão/imunologia , Homologia de Sequência de Aminoácidos , Especificidade da Espécie , Ressonância de Plasmônio de Superfície , Distribuição TecidualRESUMO
Oncostatin M (OSM) is known to inhibit the growth of melanocytes and early-stage melanomas, but this ability is lost with melanoma progression. The biological effects of OSM involve the activation of Janus kinases (Jak) and signal transducer and activator of transcription (STAT) factors. Since SOCS (suppressor of cytokine signaling) a recently described family of regulatory proteins, has been shown to act through down-regulation of Jak-STAT signaling, we investigated their putative role in the inhibition of OSM signaling in the human melanoma cell line A375. We observed that, among the SOCS family members examined, only SOCS-3 mRNA was strongly and rapidly induced by OSM. SOCS-3 protein was present within 1h and rapidly declined thereafter. Constitutive expression of SOCS-3 protein completely abolished the activation of the Jak-STAT signaling pathway as well as the Ras-MAP kinase pathway. As a result, A375 cells acquired an OSM-resistant phenotype. Our findings demonstrate that SOCS-3 is a potent regulator of OSM response and suggest that dysregulation of SOCS-3 expression could provide a mechanism for OSM resistance acquisition during tumour progression.
Assuntos
Melanoma/metabolismo , Peptídeos/metabolismo , Proteínas/fisiologia , Proteínas Repressoras , Transdução de Sinais/fisiologia , Fatores de Transcrição , Sequência de Bases , Primers do DNA , Ativação Enzimática , Humanos , Melanoma/patologia , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Oncostatina M , Proteínas Recombinantes/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteína 3 Supressora da Sinalização de Citocinas , Proteínas Supressoras da Sinalização de Citocina , Células Tumorais CultivadasRESUMO
Manufacturing and using DNA chips in a laboratory, while respecting legality and good practices, require a review of the regulatory framework and relevant documentation for implementing a quality assurance system. Using DNA chips, either as a research tool, or as an in vitro diagnostic medical device, does not come within the same regulations: none in the first case, and european directive 98/79/CE in the second one. It is the same for research practice, for which the law to be enforced has been primarily conditioned to ethics, while carrying out medical analyses has been framed in France by the GBEA. The regulatory approach laid down in the GBEA is a first step for implementing a quality assurance system, but this must be extended to the manufacturing process of DNA chips. International standards (ISO 9001: 2000, ISO/IEC 15189...) provide documentation to meet this last requirement, but also enable one to carry on the quality approach up to the certification of the laboratory or its accreditation.
Assuntos
Laboratórios/normas , Análise de Sequência com Séries de Oligonucleotídeos , Medicina Clínica , França , Laboratórios/legislação & jurisprudência , Controle de QualidadeRESUMO
Kleine-Levin syndrome belongs to the recurrent hypersomnias group. It is a rare and benignant disease, occurring in young men 10 to 25 years old. The diagnosis is first clinical and the hypersomniac episodes, joined to psychiatric symptoms, are irregularly recurrent during few years. Diagnosis is uneasy during the first episode and in the attenuated forms... 500 cases have been described all around the world but it's highly likely that many patients haven't been listed. This syndrome, just like Gélineau disease, stands in the group of primary pathological hypersomnias. In a clinical point of view, the cardinal and constant symptom is hypersomnia. Psychiatric symptoms can be irregularly joined: megaphagia, sexual behavioural disorders, thymic disorders, personality modifications. The clinical examination is poor and aspecific. During an hypersomniac episode, a polygraphic recording during 24 or 48 hours will give diagnosis informations (fragmented and unstable sleep, reduction in stages 3 and 4 of non-REM sleep, reduction in REM sleep latency) and a biological and radiological evaluation will be necessary to exclude organic etiology (tumoral progres, infectious disease...). In a therapeutic point of view, prescription of psychostimulant drugs is recommended during fits and some treatments are used in a preventive way (lithium and carbamazepine).
Assuntos
Síndrome de Kleine-Levin/diagnóstico , Transtornos Mentais/diagnóstico , Adulto , Diagnóstico Diferencial , Humanos , Síndrome de Kleine-Levin/psicologia , Masculino , Transtornos Mentais/psicologia , Admissão do PacienteRESUMO
With advent of several treatment options in multiple myeloma (MM), a selection of effective regimen has become an important issue. Use of gene expression profile (GEP) is considered an important tool in predicting outcome; however, it is unclear whether such genomic analysis alone can adequately predict therapeutic response. We evaluated the ability of GEP to predict complete response (CR) in MM. GEP from pretreatment MM cells from 136 uniformly treated MM patients with response data on an IFM, France led study were analyzed. To evaluate variability in predictive power due to microarray platform or treatment types, additional data sets from three different studies (n=511) were analyzed using same methods. We used several machine learning methods to derive a prediction model using training and test subsets of the original four data sets. Among all methods employed for GEP-based CR predictive capability, we got accuracy range of 56-78% in test data sets and no significant difference with regard to GEP platforms, treatment regimens or in newly diagnosed or relapsed patients. Importantly, permuted P-value showed no statistically significant CR predictive information in GEP data. This analysis suggests that GEP-based signature has limited power to predict CR in MM, highlighting the need to develop comprehensive predictive model using integrated genomics approach.
Assuntos
Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/genética , Transcriptoma , Testes Genéticos , Humanos , Análise em Microsséries , Indução de Remissão , Prevenção Secundária , Sensibilidade e EspecificidadeRESUMO
Recent studies have provided direct evidence for genetic variegation in subclones for various cancer types. However, little is known about subclonal evolutionary processes according to treatment and subsequent relapse in multiple myeloma (MM). This issue was addressed in a cohort of 24 MM patients treated either with conventional chemotherapy or with the proteasome inhibitor, bortezomib. As MM is a highly heterogeneous disease associated with a large number of chromosomal abnormalities, a subset of secondary genetic events that seem to reflect progression, 1q21 gain, NF-κB-activating mutations, RB1 and TP53 deletions, was examined. By using high-resolution single-nucleotide polymorphism arrays, subclones were identified with nonlinear complex evolutionary histories. Such reordering of the spectrum of genetic lesions, identified in a third of MM patients during therapy, is likely to reflect the selection of genetically distinct subclones, not initially competitive against the dominant population but which survived chemotherapy, thrived and acquired new anomalies. In addition, the emergence of minor subclones at relapse appeared to be significantly associated with bortezomib treatment. These data support the idea that new strategies for future clinical trials in MM should combine targeted therapy and subpopulations' control to eradicate all myeloma subclones in order to obtain long-term remission.